{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:06:01Z","timestamp":1755219961571,"version":"3.43.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019187","name":"Associa\u00e7\u00e3o Portuguesa Contra a Leucemia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.htct.2025.103935","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:40:33Z","timestamp":1751665233000},"page":"103935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-1174","authenticated-orcid":false,"given":"Ana Maria","family":"Meireles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Calisto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7690-9830","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Bento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-9075","authenticated-orcid":false,"given":"Pedro Martinho","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-2080","authenticated-orcid":false,"given":"Susana","family":"Bizarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5982","authenticated-orcid":false,"given":"Manuel","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4840-590X","authenticated-orcid":false,"given":"Ana Esp\u00edrito","family":"Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-4749","authenticated-orcid":false,"given":"M\u00e1rio","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: A Ca J Clin"},{"issue":"3","key":"10.1016\/j.htct.2025.103935_bib0002","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.htct.2025.103935_bib0003","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.htct.2025.103935_bib0004","first-page":"1330","volume":"340","author":"Sawyers","year":"1999"},{"issue":"21","key":"10.1016\/j.htct.2025.103935_bib0005","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: chronic Myeloid Leukemia trialists' Collaborative Group","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.htct.2025.103935_bib0006","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0007","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","article-title":"The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors","volume":"2016","author":"Efficace","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"10","key":"10.1016\/j.htct.2025.103935_bib0008","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.htct.2025.103935_bib0009","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2025.103935_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2025.103935_bib0011","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.htct.2025.103935_bib0012","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.htct.2025.103935_bib0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.htct.2025.103935_bib0014","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.htct.2025.103935_bib0015","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clinthera.2018.12.013","article-title":"The case for real-world evidence in the future of clinical research on chronic myeloid leukemia","volume":"41","author":"Webster","year":"2019","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.htct.2025.103935_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/10781552231217694","article-title":"Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"30","author":"Collins","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0017","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.24591","article-title":"A population-based study of chronic myeloid leukemia patients treated with imatinib in first line","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.htct.2025.103935_bib0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ejhpharm-2017-001378","article-title":"Evaluation of the use, effectiveness and safety of tyrosine kinase inhibitors in chronic myelogenous leukaemia in a general university hospital","volume":"27","author":"Marquinez-Alonso","year":"2020","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0019","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1186\/s12885-022-10241-y","article-title":"A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia","volume":"22","author":"Cantoni","year":"2022","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.htct.2025.103935_bib0020","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.htct.2025.103935_bib0021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40261-018-0676-7","article-title":"Pattern of use and long-term safety of tyrosine kinase inhibitors: a decade of real-world management of chronic myeloid leukemia","volume":"38","author":"Bettiol","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.htct.2025.103935_bib0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"10.1016\/j.htct.2025.103935_bib0023","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Comprehens Ca Netw"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.htct.2025.103935_bib0027","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2025.103935_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101196","article-title":"Chronic myeloid leukaemia: biology and therapy","volume":"65","author":"Wang","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.htct.2025.103935_bib0029","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023: common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925002032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137925002032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:23:53Z","timestamp":1754580233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137925002032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2531137925002032"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2025.103935","relation":{},"ISSN":["2531-1379"],"issn-type":[{"type":"print","value":"2531-1379"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2025.103935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"103935"}}